Health Sciences Acquisitions Corp

Cash fell $104.3 million in a single quarter against a $153.2 million loss, the difference largely non-cash compensation and option proceeds. There is no debt on this balance sheet — total liabilities of $117.1 million are accruals and payables — so the runway is entirely a function of the burn rate, which rose 27% year over year.

At $153.2 million a quarter, $797.8 million is roughly five quarters of spending, and the stated runway reaches a commercial launch whose enabling data does not arrive until calendar 2027 — the runway claim and the data timeline are the two facts to hold together. R&D rose 41% while G&A fell 32%, so the increase is trials, not overhead.

A routine annual meeting, but a useful marker: the successor to Health Sciences Acquisitions Corp is a functioning Nasdaq operating company whose stock closed at $24.84 on 31 March 2026, the outcome a sponsor track record should register. Note also a discrepancy in OUR record, not in the document: this CIK is stored with status LIQUIDATED while it is plainly filing as an operating Nasdaq company that completed its combination. A vehicle that completed a combination is not liquidated, and the status wants review.

The earnout is unchanged and remains the sharpest term: up to 20,000,000 further shares, 10,000,000 if the volume-weighted average price reaches at least $17.50 for any 20 trading days in a 30-trading-day period before March 31, 2023, and 10,000,000 at $31.50 before March 31, 2025. A change of control, a liquidation or winding up, a bankruptcy proceeding or an assignment for the benefit of creditors before March 31, 2025 deems unissued Earnout Shares earned regardless of whether the price tests were met.

The Sellers can earn up to 20,000,000 further shares: 10,000,000 if the volume-weighted average price reaches at least $17.50 for any 20 trading days within a 30-trading-day period before March 31, 2023, and 10,000,000 at $31.50 before March 31, 2025. The acceleration clause matters more than the thresholds — on a change of control, a liquidation, a bankruptcy proceeding or an assignment for the benefit of creditors before March 31, 2025, unissued Earnout Shares are deemed earned whether or not the price test was met, unless change-of-control consideration is below those thresholds.

What changed: Immunovant, Inc. (Nasdaq: IMVT) filed its 10-Q for the quarter ended June 30, 2026, its fiscal first quarter, with 206,552,682 shares outstanding as of August 3, 2026. Cash and equivalents fell to $797,798 thousand from $902,110 thousand at March 31, 2026 and total assets to $852,490 thousand from $957,014 thousand, while accrued expenses and other current liabilities rose to $106,964 thousand from $96,881 thousand, taking total liabilities to $117,102 thousand. Total stockholders' equity fell to $735,388 thousand from $852,592 thousand and the accumulated deficit reached $1,898,353 thousand. Why it matters: Cash fell $104.3 million in a single quarter against a $153.2 million loss, the difference largely non-cash compensation and option proceeds. There is no debt on this balance sheet — total liabilities of $117.1 million are accruals and payables — so the runway is entirely a function of the burn rate, which rose 27% year over year.

What changed: Immunovant, Inc. (Nasdaq: IMVT) furnished a press release reporting results for its fiscal first quarter ended June 30, 2026. Cash and equivalents were $797.8 million, which the company states provides runway to the potential commercial launch of IMVT-1402 in Graves' disease based on its current operating plan. Why it matters: At $153.2 million a quarter, $797.8 million is roughly five quarters of spending, and the stated runway reaches a commercial launch whose enabling data does not arrive until calendar 2027 — the runway claim and the data timeline are the two facts to hold together. R&D rose 41% while G&A fell 32%, so the increase is trials, not overhead.